04/09/2026 US FDA grants accelerated approval for camizestrant combination as first-line treatment of ESR1-mutated advanced ER+ Breast cancer US FDA grants accelerated approval for camizestrant combination as first-line treatment of ESR1-mutated advanced ER+ Breast cancer (Ref) AstraZeneca announced that the US FDA has granted accelerated approval for Etcamah (camizestrant; next-generation oral SERD and complete ER antagonist) in combination with a CDK4/6 inhibitor for first-